Literature DB >> 30151743

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT.

Hendrik Rathke1, Clemens Kratochwil2, Ralph Hohenberger3, Frederik Lars Giesel2, Frank Bruchertseifer4, Paul Flechsig2, Alfred Morgenstern4, Matti Hein5, Peter Plinkert3, Uwe Haberkorn2,6, Olcay Cem Bulut3,5.   

Abstract

PURPOSE: The main side effect of prostate-specific membrane antigen targeting alpha therapy (PSMA TAT) is dry mouth syndrome. Inflammation of the salivary glands and consequent reduced salivary function have been reported in patients after radioiodine therapy. The beneficial effects of sialendoscopy on radiation-induced inflammation in tissue are well known. Thus sialendoscopy with dilatation, saline irrigation and steroid injections (prednisolone) was performed before and after 225Ac-PSMA-617 TAT to reduce inflammatory effects in the salivary glands and to improve or prevent xerostomia.
METHODS: Eleven men with metastatic castration-resistant prostate cancer (mean age 68.5 years, range 58-80 years) underwent sialendoscopy, dilatation, saline irrigation and steroid injection of both submandibular and both parotid glands before or after every cycle of 225Ac-PSMA-617 TAT. Sialendoscopy and steroid injection were performed by a senior ENT physician. Quality of life was evaluated using two health-related quality of life (HRQOL) questionnaires, the Xerostomia Questionnaire (XQ) and the Xerostomia Inventory (XI) before and 3 months after the intervention.
RESULTS: In all 11 patients both parotid and both submandibular glands were affected by radiation sialadenitis and sialendoscopy was performed. The patients experienced no complications after sialendoscopy, and showed a significant improvement in HRQOL as measured using the XQ and XI. After sialendoscopy the XQ score decreased significantly from 77.7 ± 13.6 to 42.7 ± 14.8 (p = 0.003) and the XI score decreased from 44.5 ± 6.9 to 25.8 ± 12.8 (p = 0.003). Due to the limited number of patients we only report tendencies.
CONCLUSION: Sialendoscopy with dilatation, saline irrigation and steroid injection had beneficial effects on salivary gland function and HRQOL in patients undergoing 225Ac-PSMA-617 RLT. However, even with sialadenoscopic support after multiple cycles of TAT, salivary gland function was reduced and xerostomia was present. Therefore, not only inflammation but also the direct effect of radiation is a putative cause of dry mouth. Further research is necessary to determine the main side effects of PSMA TAT.

Entities:  

Keywords:  Ac-225; PSMA-617; PSMA-RLT; TAT; Xerostomia

Mesh:

Substances:

Year:  2018        PMID: 30151743     DOI: 10.1007/s00259-018-4135-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

1.  Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy.

Authors:  Christian Filss; Alexander Heinzel; Berthold Miiller; Andreas T J Vogg; Karl-Josef Langen; Felix M Mottaghy
Journal:  Nuklearmedizin       Date:  2018-02-21       Impact factor: 1.379

2.  [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].

Authors:  K H Bohuslavizki; W Brenner; S Lassmann; S Tinnemeyer; S Kalina; M Clausen; E Henze
Journal:  Nuklearmedizin       Date:  1997-04       Impact factor: 1.379

3.  TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.

Authors:  Lise Eckhoff; Mette Nielsen; Susanne Moeller; Ann Knoop
Journal:  Acta Oncol       Date:  2011-08-09       Impact factor: 4.089

4.  Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer.

Authors:  A Eisbruch; H M Kim; J E Terrell; L H Marsh; L A Dawson; J A Ship
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

5.  The Xerostomia Inventory: a multi-item approach to measuring dry mouth.

Authors:  W M Thomson; J M Chalmers; A J Spencer; S M Williams
Journal:  Community Dent Health       Date:  1999-03       Impact factor: 1.349

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

8.  First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Shutian Ruan; Serge K Lyashchenko; Jorge A Carrasquillo; Glenn Heller; Danny F Martinez; Sarah M Cheal; Jason S Lewis; Martin Fleisher; Jennifer S Keppler; Robert E Reiter; Anna M Wu; Wolfgang A Weber; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  J Nucl Med       Date:  2016-08-11       Impact factor: 10.057

9.  Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands.

Authors:  Ludwike W M van Kalmthout; Marnix G E H Lam; Bart de Keizer; Gerard C Krijger; Tessa F T Ververs; Rememrt de Roos; Arthur J A T Braat
Journal:  EJNMMI Res       Date:  2018-07-03       Impact factor: 3.138

10.  Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.

Authors:  Florian C Gaertner; Khalil Halabi; Hojjat Ahmadzadehfar; Stefan Kürpig; Elisabeth Eppard; Charalambos Kotsikopoulos; Nikolaos Liakos; Ralph A Bundschuh; Holger Strunk; Markus Essler
Journal:  Oncotarget       Date:  2017-07-06
View more
  22 in total

1.  Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents.

Authors:  Jyoti Roy; Blake M Warner; Falguni Basuli; Xiang Zhang; Karen Wong; Thomas Pranzatelli; Anita T Ton; John A Chiorini; Peter L Choyke; Frank I Lin; Elaine M Jagoda
Journal:  Cancer Biother Radiopharm       Date:  2020-02-19       Impact factor: 3.099

2.  Value proposition of PSMA-targeted α-particle radioligand therapy in metastatic prostate cancer.

Authors:  Hossein Jadvar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-11       Impact factor: 9.236

3.  Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy.

Authors:  Sissy M Jhiang; Jennifer A Sipos
Journal:  Endocr Relat Cancer       Date:  2021-09-03       Impact factor: 5.900

4.  The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study.

Authors:  Wesley R Armstrong; Andrei Gafita; Shaojun Zhu; Pan Thin; Kathleen Nguyen; Rejah Alano; Stephanie Lira; Kiara Booker; Linda Gardner; Tristan Grogan; David Elashoff; Martin Allen-Auerbach; Magnus Dahlbom; Johannes Czernin; Jeremie Calais
Journal:  J Nucl Med       Date:  2021-01-28       Impact factor: 11.082

5.  A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.

Authors:  Teja Muralidhar Kalidindi; Sang-Gyu Lee; Katerina Jou; Goutam Chakraborty; Myrto Skafida; Scott T Tagawa; Neil H Bander; Heiko Schoder; Lisa Bodei; Neeta Pandit-Taskar; Jason S Lewis; Steven M Larson; Joseph R Osborne; Naga Vara Kishore Pillarsetty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-25       Impact factor: 10.057

6.  Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.

Authors:  Claudia Arndt; Ralf Bergmann; Franziska Striese; Keresztély Merkel; Domokos Máthé; Liliana R Loureiro; Nicola Mitwasi; Alexandra Kegler; Frederick Fasslrinner; Karla Elizabeth González Soto; Christin Neuber; Nicole Berndt; Noemi Kovács; David Szöllősi; Nikolett Hegedűs; Gyula Tóth; Jan-Philipp Emmermann; Kuzhuvelil B Harikumar; Tibor Kovacs; Michael Bachmann; Anja Feldmann
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

7.  225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Authors:  Mike Sathekge; Frank Bruchertseifer; Otto Knoesen; Florette Reyneke; Ismaheel Lawal; Thabo Lengana; Cindy Davis; Johncy Mahapane; Ceceila Corbett; Mariza Vorster; Alfred Morgenstern
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-19       Impact factor: 9.236

8.  Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients.

Authors:  Lena M Mittlmeier; Matthias Brendel; Leonie Beyer; Nathalie L Albert; Andrei Todica; Mathias J Zacherl; Vera Wenter; Annika Herlemann; Alexander Kretschmer; Stephan T Ledderose; Nina-Sophie Schmidt-Hegemann; Wolfgang G Kunz; Jens Ricke; Peter Bartenstein; Harun Ilhan; Marcus Unterrainer
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244

9.  Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study.

Authors:  Jyoti Roy; Blake M Warner; Falguni Basuli; Xiang Zhang; Changyu Zheng; Corrine Goldsmith; Tim Phelps; Karen Wong; Anita T Ton; Rick Pieschl; Margaret E White; Rolf Swenson; John A Chiorini; Peter L Choyke; Frank I Lin
Journal:  EJNMMI Res       Date:  2021-07-21       Impact factor: 3.138

10.  Potential Applications of 68Ga-PSMA-11 PET/CT in the Evaluation of Salivary Gland Uptake Function: Preliminary Observations and Comparison with 99mTcO4 - Salivary Gland Scintigraphy.

Authors:  Yanhong Zhao; Yuxiao Xia; Huipan Liu; Zi Wang; Yue Chen; Wei Zhang
Journal:  Contrast Media Mol Imaging       Date:  2020-01-11       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.